By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ophthalmic glaucoma agents > Betaxolol ophthalmic > Betaxolol Ophthalmic Dosage
Ophthalmic glaucoma agents
https://themeditary.com/dosage-information/betaxolol-ophthalmic-dosage-10797.html

Betaxolol Ophthalmic Dosage

Drug Detail:Betaxolol ophthalmic (Betaxolol ophthalmic [ bay-tax-oh-lol-off-thal-mik ])

Drug Class: Ophthalmic glaucoma agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Intraocular Hypertension

0.25% suspension: One drop in the affected eye(s) twice a day
0.5% solution: One to two drops in the affected eye(s) twice a day

Comments:

  • In some patients, the intraocular pressure lowering responses may require a few weeks to stabilize.
  • If the intraocular pressure is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors may be instituted.

Use: To lower intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension

Usual Adult Dose for Glaucoma (Open Angle)

0.25% suspension: One drop in the affected eye(s) twice a day
0.5% solution: One to two drops in the affected eye(s) twice a day

Comments:

  • In some patients, the intraocular pressure lowering responses may require a few weeks to stabilize.
  • If the intraocular pressure is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors may be instituted.

Use: To lower intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension

Usual Pediatric Dose for Intraocular Hypertension

0.25% suspension: One drop in the affected eye(s) twice a day

Comments:

  • In some patients, the intraocular pressure lowering responses may require a few weeks to stabilize.
If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors may be instituted.

Use: To lower intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension

Usual Pediatric Dose for Glaucoma (Open Angle)

0.25% suspension: One drop in the affected eye(s) twice a day

Comments:

  • In some patients, the intraocular pressure lowering responses may require a few weeks to stabilize.
If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors may be instituted.

Use: To lower intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

0.5% solution: Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements:

  • Protect from light
  • Store product in the original outer carton.
  • The product should be discarded one month after opening.

Patient advice:
  • The bottle should be shaken well prior to each use.
  • Patients should also be advised that if they develop any intercurrent ocular condition (e.g., trauma, ocular surgery, or infection), they should immediately seek their physician's advice concerning the continued use of this drug.
  • When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced.
  • Do not touch dropper tip to any surface.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by